Evidence map›Paper›PMID 35092352›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

hESCs-Derived Early Vascular Cell Spheroids for Cardiac Tissue Vascular Engineering and Myocardial Infarction Treatment.

Yang Liu, Yifan Zhang, Tianxiao Mei, Hao Cao, Yihui Hu, Wenwen Jia, Jing Wang, Ziliang Zhang, Zhan Wang, Wenjun Le and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Bioprinted Organoids: An Innovative Engine in Biomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Yang LiuInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.
Yifan ZhangInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.
Tianxiao MeiInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.
Hao CaoDepartment of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Yihui HuInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.
Wenwen JiaNational Stem Cell Translational Resource Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Jing WangInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.
Ziliang ZhangInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.
Zhan WangDepartment of Internal Medicine, Section on Molecular Medicine, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA.
Wenjun LeInstitute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Medicine, Tongji University, Shanghai, 200092, China.ORCID 0000-0003-3972-1422
Zhongmin LiuDepartment of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Shanghai East Hospital · CNWake Forest University · US

Funding

Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone ZJ2018-ZD-004National Key Research and Development Program of China 2017YFA0105600National Natural Science Foundation of China 82100272Peak Disciplines (Type IV) of Institutions of Higher Learning in ShanghaiShanghai Pujiang Program 2020PJD052Shanghai Science and Technology Innovation Fund 201409001200
6 · The paper itself

Abstract

Transplanting functional cells to treat myocardial infarction (MI), a major disease threatening human health, has become the focus of global therapy. However, the efficacy has not been well anticipated, partly due to the lack of microvascular system that supplies nutrients and oxygen. Here, spheroids of early vascular cells (EVCs) derived from human embryonic stem cells (hESCs), rather than single-cell forms, as transplant "seeds" for reconstructing microvascular networks, are proposed. Firstly, EVCs containing CD34

Indexed as

BioprintingHuman Embryonic Stem CellsMyocardial InfarctionAnimalsEndothelial CellsHumansMiceTissue Engineering3D bioprintingcell spheroidsembryonic stem cellsmyocardial infarctionvascularized tissues

Identifiers

PMID35092352
PMCPMC8948571
OpenAlexW4210385645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.